Carmell Awarded U.S. Patent for Plasma-based Materials in Drug Delivery

By Julie A. Vetalice

Carmell Therapeutics received U.S. Patent No. 9,364,503, broadly covering the use of plasma-based materials (PBMs) as vehicles for delivering antimicrobials, analgesics, anti-inflammatory drugs and other drugs and proteins. This new patent brings Carmell’s total portfolio to 8 U.S. and 9 foreign issued patents.  Additional U.S. and foreign patents remain pending.

PBMs are manufactured from pooled human blood plasma that is treated to inactivate viruses, then freeze-dried into powder and plasticized to create pastes, putties, scaffolds, plugs and screws. Carmell's first product in development is REPAIR™ Putty to augment bone fractures. The new patent focuses on novel PBMs that can deliver antimicrobials locally.

Studies have shown that use of REPAIR plasma-based bone putty reduced infections, sped bone healing and promoted rapid wound closure in the treatment of open tibia fractures.

Sources: Carmell Therapeutics, ORTHOWORLD Inc.


Product Labels: PRP/Cell-Based/Osteoinductive Materials

Tags: Patent